Business Description
Noile-Immune Biotech Inc
ISIN : JP3759560000
Description
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.98 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 49.93 | |||||
| Beneish M-Score | -3.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 51 | |||||
| 3-Year EBITDA Growth Rate | -11.5 | |||||
| 3-Year EPS without NRI Growth Rate | -24.6 | |||||
| 3-Year FCF Growth Rate | -45.4 | |||||
| 3-Year Book Growth Rate | 30.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.34 | |||||
| 9-Day RSI | 34.85 | |||||
| 14-Day RSI | 37.57 | |||||
| 6-1 Month Momentum % | -18.69 | |||||
| 12-1 Month Momentum % | -13.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 66.55 | |||||
| Quick Ratio | 66.4 | |||||
| Cash Ratio | 65.05 | |||||
| Days Inventory | 9443.5 | |||||
| Days Sales Outstanding | 390.99 | |||||
| Days Payable | 31675.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.8 | |||||
| Operating Margin % | -316.73 | |||||
| Net Margin % | -318.08 | |||||
| FCF Margin % | -283.41 | |||||
| ROE % | -17.53 | |||||
| ROA % | -17.12 | |||||
| ROIC % | -501.28 | |||||
| ROC (Joel Greenblatt) % | -928.16 | |||||
| ROCE % | -17.44 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 22.2 | |||||
| PB Ratio | 1.37 | |||||
| Price-to-Tangible-Book | 1.38 | |||||
| EV-to-EBIT | -1.98 | |||||
| EV-to-EBITDA | -1.98 | |||||
| EV-to-Revenue | 6.29 | |||||
| EV-to-FCF | -2.12 | |||||
| Price-to-Net-Current-Asset-Value | 1.38 | |||||
| Price-to-Net-Cash | 1.41 | |||||
| Earnings Yield (Greenblatt) % | -50.28 | |||||
| FCF Yield % | -12.68 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Noile-Immune Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 308.061 | ||
| EPS (TTM) (円) | -22.64 | ||
| Beta | 0 | ||
| Volatility % | 76.63 | ||
| 14-Day RSI | 37.57 | ||
| 14-Day ATR (円) | 4.732648 | ||
| 20-Day SMA (円) | 165.5 | ||
| 12-1 Month Momentum % | -13.43 | ||
| 52-Week Range (円) | 121 - 353 | ||
| Shares Outstanding (Mil) | 43.3 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Noile-Immune Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Noile-Immune Biotech Inc Stock Events
| Event | Date | Price(円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Noile-Immune Biotech Inc Frequently Asked Questions
What is Noile-Immune Biotech Inc(TSE:4893)'s stock price today?
The current price of TSE:4893 is 円159.00. The 52 week high of TSE:4893 is 円353.00 and 52 week low is 円121.00.
When is next earnings date of Noile-Immune Biotech Inc(TSE:4893)?
The next earnings date of Noile-Immune Biotech Inc(TSE:4893) is .
Does Noile-Immune Biotech Inc(TSE:4893) pay dividends? If so, how much?
Noile-Immune Biotech Inc(TSE:4893) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers